Drugs that contain Fenofibrate
1. Antara (micronized) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101574 | LUPIN | Pharmaceutical composition containing fenofibrate and the preparation method |
Aug, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7863331 | LUPIN | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
Aug, 2020
(3 years ago) | |
| US8026281 | LUPIN | Treating metabolic syndrome with fenofibrate |
Apr, 2025
(11 months from now) | |
| US9314447 | LUPIN | Reduced dose pharmaceutical compositions of fenofibrate |
May, 2033
(9 years from now) | |
Market Authorisation Date: 18 October, 2013
Treatment: Treating hypertriglyceridemias with reduction of food effect; Treating primary hypercholesterolemia and mixed dyslipidemia; Treating severe hypertriglyceridemia
Dosage: CAPSULE;ORAL
ANTARA (MICRONIZED) family patents
2. Fenoglide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8481078 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(5 months from now) | |
| US8124125 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(5 months from now) | |
| US9173847 | SALIX | Tablet comprising a fibrate |
Oct, 2024
(5 months from now) | |
| US7658944 | SALIX | Solid dosage form comprising a fibrate |
Dec, 2024
(7 months from now) | |
Market Authorisation Date: 10 August, 2007
Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total tri...
Dosage: TABLET;ORAL
FENOGLIDE family patents
3. Lipofen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5545628 | CIPHER PHARMS INC | Pharmaceutical composition containing fenofibrate |
Jan, 2015
(9 years ago) | |
Market Authorisation Date: 11 January, 2006
Treatment: Treatment of hypercholesterolemia and/or hypertriglyceridemia
Dosage: CAPSULE;ORAL
LIPOFEN family patents
4. Tricor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6652881 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability |
Jan, 2018
(6 years ago) | |
| US6277405 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7041319 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailabilty |
Jan, 2018
(6 years ago) | |
| US7037529 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6277405 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6074670 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6652881 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability |
Jan, 2018
(6 years ago) | |
| US6589552 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6375986 | ABBVIE | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(3 years ago) | |
| US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(1 year, 2 months ago) | |
| US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(1 year, 2 months ago) | |
Market Authorisation Date: 04 September, 2001
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, total-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to t...
Dosage: TABLET;ORAL
TRICOR family patents
5. Triglide patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6696084 | SKYEPHARMA AG | Spray drying process and compositions of fenofibrate |
Sep, 2021
(2 years ago) | |
Market Authorisation Date: 07 May, 2005
Treatment: A method of treating dyslipidemia and dyslipoproteinemia using a dosage form that can provide an effective amount of fenofibrate to a patient in a fasted state which is at least 90% of the auc amount ...
Dosage: TABLET;ORAL
TRIGLIDE family patents